Is the Food and Drug Administration withholding certain touchy drug trial data to protect the sensitive corporate secrets of pharmaceutical companies?

被引：1
|
作者：
Seife, Charles [1 ]
机构：
[1] NYU, Journalism, New York, NY 10003 USA
来源：
SCIENTIFIC AMERICAN | 2018年 / 318卷 / 02期
关键词：
D O I：
10.1038/scientificamerican0218-38
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
[No abstract available]
引用
收藏
页码：38 / 43
页数：6
相关论文
共 16 条
  • [1] Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
    Modi, Natansh D.
    Abuhelwa, Ahmad Y.
    McKinnon, Ross A.
    Boddy, Alan, V
    Haseloff, Mark
    Wiese, Michael D.
    Hoffmann, Tammy C.
    Perakslis, Eric D.
    Rowland, Andrew
    Sorich, Michael J.
    Hopkins, Ashley M.
    JAMA ONCOLOGY, 2022, 8 (09) : 1310 - 1316
  • [2] Audit of data sharing by pharmaceutical companies for anticancer medicines approved by the US food and drug administration
    Modi, Natansh D.
    Hopkins, AshleyM.
    Sorich, Michael J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 171 - 172
  • [3] US Food and Drug Administration's social media usage guidelines: are pharmaceutical companies compliant?
    Dayal, Disha
    Multani, Shaleen
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 : 27 - 28
  • [4] Status of pharmaceutical companies' dermatology-related postmarketing study commitments to the Food and Drug Administration (FDA)
    Bognet, R. A.
    Chiang, D. S.
    Katz, K. A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 : 48 - 48
  • [5] Pharmaceutical Research and Manufacturers of America/Food and Drug Administration Cooperation in Building Capabilities for Electronic Submission of Postmarketing Safety Data
    William S. Calvert
    Virginia Holihan
    Drug information journal : DIJ / Drug Information Association, 1999, 33 (4): : 1093 - 1099
  • [6] Pharmaceutical Research and Manufacturers of America Food and Drug Administration cooperation in building capabilities for electronic submission of postmarketing safety data
    Calvert, WS
    Holihan, V
    DRUG INFORMATION JOURNAL, 1999, 33 (04): : 1093 - 1099
  • [7] The Financing of Drug Trials by Pharmaceutical Companies and Its Consequences Part 2: A Qualitative, Systematic Review of the Literature on Possible Influences on Authorship, Access to Trial Data, and Trial Registration and Publication
    Schott, Gisela
    Pachl, Henry
    Limbach, Ulrich
    Gundert-Remy, Ursula
    Lieb, Klaus
    Ludwig, Wolf-Dieter
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2010, 107 (17): : 295 - U13
  • [8] Food and Drug Administration Analysis of Ticagrelor Using Data From an Enriched Trial to Evaluate Benefit-Risk Difference in an Unstudied Population
    McDowell, Tzu-Yun
    Blank, Melanie
    Lawrence, John
    Stockbridge, Norman
    CIRCULATION, 2016, 134 (19) : 1500 - 1502
  • [9] The US Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial
    Durmowicz, Anthony G.
    Lim, Robert
    Rogers, Hobart
    Rosebraugh, Curtis J.
    Chowdhury, Badrul A.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2018, 15 (01) : 1 - 2
  • [10] Does the rising placebo response impact antihypertensive clinical trial outcomes? An analysis of data from the Food and Drug Administration 1990-2016
    Khan, Arif
    Mar, Kaysee Fahl
    Schilling, Joshua
    Brown, Walter A.
    PLOS ONE, 2018, 13 (02):
12